Long-term effectiveness of danazol corticosteroids and cytotoxic drugs in the treatment of hematologic manifestations of systemic lupus erythematosus

Abstract

The purpose of this study was to compare the long-termeffectivenessamong danazol, corticosteroids, cytotoxics, and dapsone in the treatment of hematological manifestations of systemic lupus erythematosus (SLE). Medical charts of all patients seen at the Rheumatic Disease Unit from January to December of 1998 were reviewed. Patient characteristics, disease and treatment information were collected. The main outcome measures were the cause of and time to discontinuation of drugs used to treat hematological manifestations of SLE resulting from all causes, mainly toxicity and inefficacy or both. Bivariate analysis including one-way ANOVA and ϰ² tests were used to comparedifferencesbetween means and proportions, respectively.Survivalcurvesamong the different drugs were evaluated using the Kaplan - Meier method. Multivariate analysis (Cox-regression) was used to adjust for potential confounders. After all medical records were reviewed 41 cases were eligible. Two cases had hemolytic anemia, 34 had thrombocytopenia, and five had both. These cases had received a total of 121 cycles of treatment at different times and they represent the study population (corticosteroids n = 37, danazol n = 51, citotoxic drugs n = 29, and dapsone n = 4). Crude rates of discontinuations due to any cause, toxicity and inefficacy were not statistically significant among the drugs. However, the Kaplan - Meier curves showed statistically significant difference for discontinuations due to all causes as well as inefficacy. Prednisone and cytotoxic drugs had the lowest probability of continuation. In contrast, there were not statistically significant differencesamong the drugs with respect to first relapse. This is the first study examining the long-term termination rates of several drugs used to treat hematological manifestations of SLE. Using rates of discontinuationadjustedfor time there were statisticallysignificant differencesamong the drugs. Danazol had the highest probability of continuation.

Keywords

thrombocytopenia hemolitic anemia danazol lupus treatment

Get full access to this article

View all access options for this article.

References

DiFino SM , Lachant NA , Kirshner JJ , Gottlieb AJ. Adult idiopathic thrombocytopenic purpura. Clinical findings and response to therapy . Am J Med 1980; 69: 430-442 .

Lavalle C , Hurtado R , Quezada JJ , Cabral A , Fraga A. Hemocytopenia as initial manifestation of systemic lupus erythematosus. Prognostic significance . Clin Rheumatol 1983; 2: 227-232 .

Mestanza-Peralta M , Ariza-Ariza R , Cardiel MH , Alcocer-Varela J. Thrombocytopenic purpura as initial manifestation of systemic lupus erythematosus . J Rheumatol 1997; 24: 867-870 .

Ward MM , Pyun E , Studenski S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus . Arch Intern Med 1996; 156: 1337-1344 .

Pizzuto J , Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenia purpura: multicentric trial of the Cooperative Latin América Group on Hemostasis and Thrombosis . Blood 1984; 64: 1179-1183 .

Stasi R , Stipa E , Masi M , Cecconi M , Scimó MT , Oliva F et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura . Am J Med 1995; 98: 436-442 .

Agnello V , Pariser K , Gell J , Gelfand J , Turksoy RN. Preliminary observations on danazol therapy of systemic lupus erytheamtosus: effects on DNA antibodies, thrombocytopenia and complement . J Rheumatol 1983; 10: 682-687 .

West SG , Johnson SC. Danazol for the treatment of refractory auto-immune thrombocytopenia in systemic lupus erythematosus . Ann Intern Med 1988; 108: 703-706 .

Cervera H , Jara LJ , Pizarro S , Enkerlin HL , Fernandez M , Medina F , Fraga A , et al. Danazol for systemic lupus erythematosus with refractory autoimmune thrombocytopenia or Evan’s syndrome . J Rheumatol 1995; 22: 1867-1871 .

10.

Finch SC , Castro O , Cooper M , Covey W , Erichson R , McPhedran P. Immunosuppressive therapy of chronic idiopathic thrombocytopenic purpura . Am J Med 1974; 56: 4-12 .

11.

Boumpas DT , Barez S , Klippel JH , Balow JE. Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus . Ann Intern Med 1990; 112: 674-677 .

12.

Sugiyama M , Ogasawara H , Kaneko H , Hishikawa T , Sekigawa I , Iida N et al. Effect of extremely low dose cyclosporine treatment on the thrombocytopenia in systemic lupus erythematosus . Lupus 1998; 7: 53-56 .

13.

ter Borg EJ , Kallenberg CG. Treatment of severe thrombocytopenia in systemic lupus erythematosus with intravenous gammaglobulin . Ann Rheum Dis 1992; 51: 1149-1151 .

14.

Feinglass S , Deodhar A. Treatment of lupus-induced thrombocytopenia with recombinant human interleukin-11 . Arthritis Rheum 2001; 44: 170-175 .

15.

Kokori SI , Ioannidis JPA , Voulgarelis M , Tzioufas AG , Moutsopoulos HM. Autoimmune hemolytic anemia in patients with systemic lupus erythematosus . Am J Med 2000; 108: 198-204 .

16.

Tan EM , Cohen AS , Fries JF , Masi AT , McShane DJ , Rothfield NF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271-1277 .

17.

Rivero SJ , Alger M , Alarcón-Segovia D. Splenectomy for hemocytopenia in systemic lupus erythematosus. A controlled appraisal . Arch Intern Med 1979; 139: 773-776 .

18.

Hall S , McCormick JL Jr , Greipp PR , Michet CJ Jr , McKenna CH. Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus . Ann Intern Med 1985; 102: 325-328 .

19.

Jacobs P , Wood L , Dent DM. Splenectomy and the thrombocytopenia of systemic lupus erythematosus . Ann Intern Med 1986; 105: 971-972 .

20.

Hakim AJ , Machin SJ , Isenberg DA. Autoimmune thrombocytopenia in primary antiphospholipid syndrome and systemic lupus erythematosus: the response to splenectomy . Semin Arthritis Rheum 1998; 28: 20-25 .

21.

Maini A , Levine RL.

Safety and efficacy of oral dapsone in the treatment of immune thrombocytopenia (ITP) in patients with and without HIV infection. [Abstract.]

Blood 2000; 96(II Pt 2): 66b-67b .

22.

Rovó AI , Petrlik E , Pierdominici M , Huberman AS.

Dapsone: a therapeutical option for immunologic thrombocytopenic purpura. [Abstract.]

Blood 2001; 98(II Pt 2): 64b-65b .